Indication for IV caspofungin therapy | Monotherapy (N= 85) n (%) | Combination therapy (N = 18) n (%) | Overall (N = 103) n (%) |
---|---|---|---|
Caspofungin first-line therapy | 15 (17.6) | 5 (27.8) | 20 (19.4) |
Caspofungin salvage therapy | 70 (82.4) | 13 (72.2) | 83 (80.6) |
Clinical refractory to first-line antifungal | 48 (68.6) | 10 (76.9) | 58 (69.0) |
Microbiological refractory to first-line antifungal | 6 (8.6) | 1 (7.7) | 7 (8.4) |
Toxicity | |||
• Nephrotoxicity to first-line antifungal | 2 (2.9) | 1 (7.7) | 3 (3.6) |
• Other toxicity | 6 (8.6) | 0 | 6 (7.2) |
Other* | 7 (10.0) | 1 (7.7) | 8 (9.6) |
Not reported | 1(1.4) | 0 | 1 (1.2) |